Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A2OW
|
||||
| Former ID |
DNC001068
|
||||
| Drug Name |
Otenzepad
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Heart failure [ICD9: 428; ICD10:I50] | Discontinued in Phase 2 | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H31N5O2
|
||||
| InChI |
InChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31)
|
||||
| InChIKey |
UBRKDAVQCKZSPO-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 100158-38-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
239489, 510727, 5530915, 10234472, 11426578, 12013665, 14929469, 26719787, 26752073, 44436806, 46386986, 47423785, 47499112, 47572939, 48242935, 49681762, 50034619, 50917362, 57338297, 85229917, 85788636, 91746553, 92098548, 92308468, 103181030, 103929232, 104379928, 124659038, 124886981, 129345351, 134340056, 134340317, 135066279, 135132787, 135649900, 135698213, 139732225, 144204493, 162022222, 162022958, 163122876, 170466332, 170485721, 172080425, 172657833, 179149480, 179295983, 184536610, 184547112, 204380666
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M2 | Target Info | Antagonist | [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | |||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 309). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001216) | ||||
| REF 3 | Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.